Approaching the time for our CMML interim analysis, the Final Report of the ACTIV-5 trial, the successful completion of the S. Korean covid safety trial, the future of our CAR-T patented treatment program, potential partnership interest in asthma and arthritis indications, and on and on, PLUS the potential to squeeze the guys who have been betting against us, I really hope we can start to see the dominos fall, and our account balances start to soar.
The CAR-T patent application had a two-fold dimension, for improving the efficacy of the treatment therapeutic, as well as for reducing neurotoxicities. I wonder if we'll see another patent Notice of Allowance for reducing neurotoxicity, unless that was made already and I didn't see it.
News 
Market Data 
Discover 
AI
